Literature DB >> 10931088

CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region.

A Balsamo1, E Cacciari, L Baldazzi, L Tartaglia, A Cassio, V Mantovani, S Piazzi, A Cicognani, P Pirazzoli, B Mainetti, F Zappulla.   

Abstract

OBJECTIVES: We have genotyped the patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency identified from March 1980 to December 1997 through a combined program of neonatal screening and case survey in the Emilia-Romagna Region (Italy). We have also analysed retrospectively the possible advantages of genotypical neonatal classification.
DESIGN: A 'phase A' of screening and clinical monitoring (March 1980-September 1983 and March 1991-December 1997) and a 'phase B' of clinical monitoring only (October 1983-February 1991) were taken into account. PATIENTS: A total of 61 patients (20 salt wasting, nine simple virilizing and 32 nonclassical forms) were genotyped, HLA typed and hormonally tested to understand better the genotype/phenotype relationship and the epidemiology and geographical distribution of associated mutations. The fully genotyped patients were classified into four mutation groups according to the degree of enzymatic activity ('null' and 'A' to 'C'). RESULT: The most frequent genotype alterations were deletion (24.1% classical, 3.3% nonclassical forms), large gene conversion (9.2% classical, 1.7% nonclassical forms), In2 splice (27.7% classical, 15.0% nonclassical forms), I172N (5.5% classical, 10.0% nonclassical forms), V281L (3.7% classical, 43.3% nonclassical forms), P453S (5.0% nonclassical forms). A significant difference (chi2 = 5.101; P < 0.025) in the distribution of classical genotypes was found in Romagna (south-east; incidence 1 : 7437 newborns) compared to Emilia (north-west; incidence 1 : 25 090 newborns). Two putative new mutations were found in our population. Little discrepancy was found between genotype and phenotype.
CONCLUSIONS: The high frequency of genotypes 'null' or 'A' in the 'phase A' vs. 'phase B' of our study confirms the usefulness of neonatal screening in preventing the death of male patients with salt wasting forms. The substantial similarity in the mutational spectrum of classical forms found in our study, based on the detection of all the classical patients of a specific area, leads us to believe that the distribution of mutations is due to the inherent characteristics of the gene locus, and that regional effects play a minor role. Prompt neonatal genotyping can be of valuable diagnostic assistance in neonatal screening for the confirmation of the diagnosis in newborns with moderately elevated 17 hydroxyprogesterone levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931088     DOI: 10.1046/j.1365-2265.2000.01048.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  21 in total

1.  Novel nonsense mutation (W22X) in CYP21A2 gene causing salt-wasting congenital adrenal hyperplasia in a compound heterozygous girl.

Authors:  L Di Pasquale; S Indovina; M Wasniewska; S Mirabelli; P Porcelli; I Rulli; G Salzano; F De Luca
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

2.  Salt wasting phenotype in a compound heterozygous girl with P482S mutation associated with anovel mutation of CYP21 gene (Q481P).

Authors:  G Di Pasquale; M Wasniewska; M Caruso; G Salzano; M Coco; F Lombardo; F De Luca
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

3.  In Sicilian ethnic group non-classical congenital adrenal hyperplasia is frequently associated with a very mild genotype.

Authors:  M Wasniewska; G Di Pasquale; I Rulli; G Salzano; M Caruso; S Indovina; L Di Pasquale; G Zirilli; F De Luca
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

4.  Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency.

Authors:  Robert C Wilson; Saroj Nimkarn; Miro Dumic; Jihad Obeid; Maryam Razzaghy Azar; Maryam Azar; Hossein Najmabadi; Fatemeh Saffari; Maria I New
Journal:  Mol Genet Metab       Date:  2007-02-01       Impact factor: 4.797

5.  [Genotypes and phenotypes in Uygur children with 21-hydroxylase deficiency in Xinjiang, China].

Authors:  Jing Li; Yan-Fei Luo; Mireguli Maimaiti
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-02

6.  Misregulation effect of a novel allelic variant in the Z promoter region found in cis with the CYP21A2 p.P482S mutation: implications for 21-hydroxylase deficiency.

Authors:  Cecilia S Fernández; Carlos D Bruque; Melisa Taboas; Noemí D Buzzalino; Lucia D Espeche; Titania Pasqualini; Eduardo H Charreau; Liliana G Alba; Pablo D Ghiringhelli; Liliana Dain
Journal:  Endocrine       Date:  2015-07-17       Impact factor: 3.633

7.  Genotype, phenotype and hormonal levels correlation in non-classical congenital adrenal hyperplasia.

Authors:  S Einaudi; E Napolitano; F Restivo; G Motta; M Baldi; G Tuli; E Grosso; N Migone; E Menegatti; C Manieri
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

8.  A large view of CYP21 locus among Sicilians and other populations: identification of a novel CYP21A2 variant in Sicily.

Authors:  M Niceta; M Bono; C Fabiano; F Pojero; F Niceta; P Sammarco; G Corsello; P Garofalo
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

9.  Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project.

Authors:  Ozge Ceyhan-Birsoy; Jaclyn B Murry; Kalotina Machini; Matthew S Lebo; Timothy W Yu; Shawn Fayer; Casie A Genetti; Talia S Schwartz; Pankaj B Agrawal; Richard B Parad; Ingrid A Holm; Amy L McGuire; Robert C Green; Heidi L Rehm; Alan H Beggs
Journal:  Am J Hum Genet       Date:  2019-01-03       Impact factor: 11.025

10.  Salt-wasting congenital adrenal hyperplasia: genotypical peculiarities in a Sicilian ethnic group.

Authors:  M Wasniewska; M Caruso; S Indovina; G Crisafulli; S Mirabelli; G Salzano; T Arrigo; F De Luca
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.